UNIGE document Scientific Article
previous document  unige:19977  next document
add to browser collection

Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome

Published in Diabetes, Obesity and Metabolism. 2009, vol. 11, no. 5, p. 445-454
Abstract Changes in diagnostic criteria have impacted on the definition of the metabolic syndrome. The central aetiological importance of insulin resistance has lessened, while the role of other cardiovascular risk factors has progressively increased. Inflammatory mediators have also been identified as crucial targets for more selective therapies in metabolic syndrome. Among several pro-inflammatory factors, adiponectin has been shown to be associated with reduced cardiovascular risk in metabolic syndrome patients. Here, we review new therapeutic approaches, which could potentially increase adiponectin levels in metabolic syndrome.
Keywords Adiponectin/*metabolismAngiotensin II Type 1 Receptor Blockers/pharmacologyAngiotensin-Converting Enzyme Inhibitors/pharmacologyAnimalsCardiovascular Diseases/complications/prevention & controlClofibric Acid/pharmacologyHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyInsulin ResistanceMetabolic Syndrome X/complications/*drug therapyMicePeroxisome Proliferator-Activated Receptors/agonistsReceptors, Cannabinoid/antagonists & inhibitorsRisk Factors
PMID: 19220391
Full text
Research groups Biologie du myocarde (22)
L'athérosclérose et ses complications cliniques (591)
(ISO format)
MONTECUCCO, Fabrizio, MACH, François. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. In: Diabetes, Obesity and Metabolism, 2009, vol. 11, n° 5, p. 445-454. doi: 10.1111/j.1463-1326.2008.00986.x https://archive-ouverte.unige.ch/unige:19977

401 hits

0 download


Deposited on : 2012-04-23

Export document
Format :
Citation style :